Newamsterdam Pharma Stock Year To Date Return
| NAMSW Stock | 14.10 0.14 1.00% |
NewAmsterdam Pharma fundamentals help investors to digest information that contributes to NewAmsterdam Pharma's financial success or failures. It also enables traders to predict the movement of NewAmsterdam Stock. The fundamental analysis module provides a way to measure NewAmsterdam Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NewAmsterdam Pharma stock.
NewAmsterdam | Year To Date Return |
NewAmsterdam Pharma Company Year To Date Return Analysis
NewAmsterdam Pharma's Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.
More About Year To Date Return | All Equity Analysis
YTD Return | = | (Mean of Monthly Returns - 1) | X | 100% |
NewAmsterdam Year To Date Return Driver Correlations
Understanding the fundamental principles of building solid financial models for NewAmsterdam Pharma is extremely important. It helps to project a fair market value of NewAmsterdam Stock properly, considering its historical fundamentals such as Year To Date Return. Since NewAmsterdam Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewAmsterdam Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewAmsterdam Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Year-To-Date typically refers to a period starting from the beginning of the current year and continuing up to the present day. Investors should becareful when comparing YTD ratios if not much of the year has occurred as research shows that YTD measures are more sensitive to early periods than late.
| Competition |
NewAmsterdam Return On Tangible Assets
Return On Tangible Assets |
|
Based on the company's disclosures, NewAmsterdam Pharma has a Year To Date Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
NewAmsterdam Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.Environmental | Governance | Social |
NewAmsterdam Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Number Of Shares Shorted | 983 | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (176.86 M) | ||||
| Net Income | (176.94 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Number Of Employees | 62 | ||||
| Beta | -0.001 | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
| Working Capital | 296.89 M | ||||
| Net Asset | 347.1 M |
About NewAmsterdam Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.